3.4.21.46	drug development	the enzyme's exosite is a target for design of specific inhibitors for inhibition of the pathway complement activation in advanced dry age-related macular degeneration	732044	
3.4.21.46	medicine	by downregulation of VEGF-D expression in a lung tumor mouse model using Deguielin, a rotenoid of the flavonoid family, tumor-associated lymphangiogenesis and lymphatic metastasis are suppressed	708769	
3.4.21.46	medicine	intravitreal VEGF-D gene transfer causes blood-retina barrier breakdown but not neovessel formation in the rabbit eye. Inflammation-like alterations in the choriocapillaries are observed in the baculoviral VEGF-D-treated eyes, but not in adenoviral VEGF-D-treated eyes at 6 days after gene transfer	699302	
3.4.21.46	medicine	is linked to the control of lymphangiogenesis and lymphatic metastasis. Epigenetic control of histone acetylation represents an important determinant of vegf-D gene expression in cancer cells	697096	
3.4.21.46	medicine	PDGF-D is present in the neointima of the arteriopathy of chronic allograft nephropathy, where it can engage PDGF-Rbeta to promote mesenchymal cell migration, proliferation, and neointima formation. PDGF-D may engage the PDGF-Rbeta to promote interstitial injury in chronic allograft injury	698194	
3.4.21.46	medicine	serum VEGF-D levels are a good biomarker for lymphatic involvement in patients with lympangioleiomyomatosis	708131	
3.4.21.46	medicine	VEGF-D plays an essential role in tumoral lymphangiogenesis and lymphatic spread, VEGF-D expression, and the intratumoral lymphatics may be clinically useful indicators for prognostic evaluation in patients with epithelial ovarian carcinoma	695580